社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
niclam
IP属地:未知
+关注
帖子 · 14
帖子 · 14
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
niclam
niclam
·
2021-12-21
Niceeee
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level<blockquote>安进(Amgen)的Otezla获得FDA批准治疗银屑病,无论严重程度如何</blockquote>
The FDA has approved Amgen Inc's Otezla (apremilast) to treat adult patients with plaque psoriasis w
Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level<blockquote>安进(Amgen)的Otezla获得FDA批准治疗银屑病,无论严重程度如何</blockquote>
看
2,800
回复
评论
点赞
6
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-19
Ftwwwww
非常抱歉,此主贴已删除
看
2,340
回复
评论
点赞
1
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-19
Virrrr
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列,辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>
The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5
Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列,辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>
看
2,794
回复
评论
点赞
5
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-19
Ftwwwwww
非常抱歉,此主贴已删除
看
2,855
回复
评论
点赞
3
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-09
Nice
Analysts Remain Bullish On Apple Over iPhone 13, AR Glasses, App Store<blockquote>分析师仍看好苹果iPhone 13、AR眼镜、App Store</blockquote>
Analysts remained bullish on Apple Inc over iPhone 13 and court order in support of App Store. Wedb
Analysts Remain Bullish On Apple Over iPhone 13, AR Glasses, App Store<blockquote>分析师仍看好苹果iPhone 13、AR眼镜、App Store</blockquote>
看
3,449
回复
1
点赞
3
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-06
Rise backkkkkkkk
非常抱歉,此主贴已删除
看
2,778
回复
1
点赞
4
编组 21备份 2
分享
举报
niclam
niclam
·
2021-12-02
Good move
非常抱歉,此主贴已删除
看
2,946
回复
评论
点赞
3
编组 21备份 2
分享
举报
niclam
niclam
·
2021-11-23
Rocketttt
非常抱歉,此主贴已删除
看
3,261
回复
评论
点赞
2
编组 21备份 2
分享
举报
niclam
niclam
·
2021-11-23
Good
非常抱歉,此主贴已删除
看
3,295
回复
评论
点赞
1
编组 21备份 2
分享
举报
niclam
niclam
·
2021-11-23
Nice
Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote>
Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%. Miz
Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote>
看
2,984
回复
1
点赞
5
编组 21备份 2
分享
举报
加载更多
暂无关注
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574938595128690","uuid":"3574938595128690","gmtCreate":1611919255517,"gmtModify":1611919255517,"name":"niclam","pinyin":"niclam","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":3,"headSize":203,"tweetSize":14,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖(非转发)","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691020174,"gmtCreate":1640099542766,"gmtModify":1640099542884,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Niceeee","listText":"Niceeee","text":"Niceeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691020174","repostId":"1198919837","repostType":4,"repost":{"id":"1198919837","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640098127,"share":"https://www.laohu8.com/m/news/1198919837?lang=zh_CN&edition=full","pubTime":"2021-12-21 22:48","market":"us","language":"en","title":"Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level<blockquote>安进(Amgen)的Otezla获得FDA批准治疗银屑病,无论严重程度如何</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1198919837","media":"Benzinga","summary":"The FDA has approved Amgen Inc's Otezla (apremilast) to treat adult patients with plaque psoriasis w","content":"<p>The FDA has approved <b>Amgen Inc's</b> Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.</p><p><blockquote>FDA已批准<b>安进公司</b>Otezla(apremilast)治疗适合光疗或全身治疗的斑块型银屑病成年患者。</blockquote></p><p> <ul> <li>With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.</li> <li>The FDA approval is based on Phase 3 ADVANCE trial data. Five times as many adults receiving oral Otezla 30 achieved the primary endpoint of Static Physician's Global Assessment response at week 16 compared to placebo (21.6% versus 4.1%).</li> <li>Otezla is approved for three indications in the U.S.</li> <li><b>Price Action:</b> AMGN shares closed at $219.99 on Monday.</li> </ul></p><p><blockquote><ul><li>随着这一扩大适应症,Otezla现在是第一个也是唯一一个被批准用于所有严重程度(包括轻度、中度和重度)斑块型银屑病成人患者的口服治疗方法。</li><li>FDA的批准是基于3期先期试验数据。与安慰剂相比,接受口服Otezla 30的成人在第16周达到静态医生总体评估反应的主要终点的人数是安慰剂的五倍(21.6%对4.1%)。</li><li>Otezla在美国被批准用于三种适应症。</li><li><b>价格走势:</b>AMGN股价周一收于219.99美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level<blockquote>安进(Amgen)的Otezla获得FDA批准治疗银屑病,无论严重程度如何</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmgen's Otezla Wins FDA Approval For Psoriasis, Regardless Of Severity Level<blockquote>安进(Amgen)的Otezla获得FDA批准治疗银屑病,无论严重程度如何</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-21 22:48</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>The FDA has approved <b>Amgen Inc's</b> Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.</p><p><blockquote>FDA已批准<b>安进公司</b>Otezla(apremilast)治疗适合光疗或全身治疗的斑块型银屑病成年患者。</blockquote></p><p> <ul> <li>With this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.</li> <li>The FDA approval is based on Phase 3 ADVANCE trial data. Five times as many adults receiving oral Otezla 30 achieved the primary endpoint of Static Physician's Global Assessment response at week 16 compared to placebo (21.6% versus 4.1%).</li> <li>Otezla is approved for three indications in the U.S.</li> <li><b>Price Action:</b> AMGN shares closed at $219.99 on Monday.</li> </ul></p><p><blockquote><ul><li>随着这一扩大适应症,Otezla现在是第一个也是唯一一个被批准用于所有严重程度(包括轻度、中度和重度)斑块型银屑病成人患者的口服治疗方法。</li><li>FDA的批准是基于3期先期试验数据。与安慰剂相比,接受口服Otezla 30的成人在第16周达到静态医生总体评估反应的主要终点的人数是安慰剂的五倍(21.6%对4.1%)。</li><li>Otezla在美国被批准用于三种适应症。</li><li><b>价格走势:</b>AMGN股价周一收于219.99美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AMGN":"安进"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198919837","content_text":"The FDA has approved Amgen Inc's Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.\n\nWith this expanded indication, Otezla is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe.\nThe FDA approval is based on Phase 3 ADVANCE trial data. Five times as many adults receiving oral Otezla 30 achieved the primary endpoint of Static Physician's Global Assessment response at week 16 compared to placebo (21.6% versus 4.1%).\nOtezla is approved for three indications in the U.S.\nPrice Action: AMGN shares closed at $219.99 on Monday.","news_type":1,"symbols_score_info":{"AMGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2800,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693096438,"gmtCreate":1639922019704,"gmtModify":1639922019783,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Ftwwwww","listText":"Ftwwwww","text":"Ftwwwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693096438","repostId":"2192976991","repostType":4,"isVote":1,"tweetType":1,"viewCount":2340,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693096504,"gmtCreate":1639921995704,"gmtModify":1639921995818,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Virrrr","listText":"Virrrr","text":"Virrrr","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693096504","repostId":"1122414343","repostType":4,"repost":{"id":"1122414343","kind":"news","pubTimestamp":1639884070,"share":"https://www.laohu8.com/m/news/1122414343?lang=zh_CN&edition=full","pubTime":"2021-12-19 11:21","market":"us","language":"en","title":"Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列,辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122414343","media":"Seeking Alpha","summary":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5","content":"<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为2.5%,主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨,而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中,<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司,溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势,本周上涨约20.7%,有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗,股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后,该公司每周上涨约25.2%,使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约23.7%,成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克(纽约证券交易所股票代码:GSK)合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻,再次提高了COVID-19疫苗的销售指引,因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势,<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%,创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新IPO的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街获得了良好的评级,但分别下跌了19.3%和约13.5%。与此同时,处方药比价平台运营商GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的,<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋,其中包括Cathie Wood的Ark Investment Management,该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列,辉瑞(Pfizer)创下十年来最佳涨幅</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax, Vir among healthcare gainers, Pfizer posts best rally in a decade<blockquote>Novavax、Vir跻身医疗保健股涨幅之列,辉瑞(Pfizer)创下十年来最佳涨幅</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Seeking Alpha</strong><span class=\"h-time small\">2021-12-19 11:21</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. <a href=\"https://laohu8.com/S/HCSG\">Healthcare</a> technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.</p><p><blockquote>标普500的医疗保健股表现优于大盘指数中的所有其他板块,涨幅约为2.5%,主要得益于并购前景。<a href=\"https://laohu8.com/S/HCSG\">医疗保健</a>科技股以及与COVID-19死灰复燃作斗争的股票领涨,而整体指数下跌约1.9%。</blockquote></p><p> Among stocks with more than $2B market capitalization and 100K average daily volume over the past week, <a href=\"https://laohu8.com/S/ARNA\">Arena Pharmaceuticals </a> dominated with a ~83.8% rise after <a href=\"https://laohu8.com/S/PFE\">Pfizer </a> agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. <a href=\"https://laohu8.com/S/CERN\">Cerner </a> also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from <a href=\"https://laohu8.com/S/ORCL\">Oracle </a> for the electronic-medical-records company.</p><p><blockquote>在过去一周市值超过20亿美元、日均成交量超过10万的股票中,<a href=\"https://laohu8.com/S/ARNA\">Arena制药公司</a>之后上涨约83.8%<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>同意以约6.7 B美元的价格收购该生物技术公司,溢价100%。<a href=\"https://laohu8.com/S/CERN\">塞尔纳</a>也加入了并购推动的涨势,本周上涨约20.7%,有报道称来自<a href=\"https://laohu8.com/S/ORCL\">神谕</a>电子病历公司。</blockquote></p><p> Vaccine developer, <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.</p><p><blockquote>疫苗开发商、<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>由于投资者欢迎世界卫生组织批准该公司的COVID-19疫苗,股价上涨约30.5%。当欧洲监管机构的专家小组将于下周审查该疫苗的营销授权时,这家总部位于马里兰州的生物技术公司可能会进一步受益。</blockquote></p><p> <a href=\"https://laohu8.com/S/BHVN\">Biohaven Pharmaceutical </a> posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, <a href=\"https://laohu8.com/S/ROIV\">Roivant Sciences </a> added ~22.6%.</p><p><blockquote><a href=\"https://laohu8.com/S/BHVN\">Biohaven制药</a>在该公司宣布NURTEC ODT(rimegepant)在以色列获得批准后,该公司每周上涨约25.2%,使其成为该偏头痛药物在美国以外的首个监管胜利。与此同时,Vir Biotechnology(纳斯达克股票代码:VIR)飙升约23.7%,成为本月第二周涨幅最大的股票之一。本周出现的更多数据证实了该公司与葛兰素史克(纽约证券交易所股票代码:GSK)合作开发的COVID-19疗法具有奥密克戎中和作用。跻身涨幅前五名的还有,<a href=\"https://laohu8.com/S/ROIV\">Roivant科学</a>增加了约22.6%。</blockquote></p><p> Notable gainer: <a href=\"https://laohu8.com/S/PFE\">Pfizer</a> (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the <a href=\"https://laohu8.com/S/NWY\">New York</a>-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.</p><p><blockquote>值得注意的赢家:<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE)本周成为头条新闻,再次提高了COVID-19疫苗的销售指引,因为迅速传播的奥密克戎变种凸显了加强注射的必要性。尽管周五突然结束了连续六天的涨势,<a href=\"https://laohu8.com/S/NWY\">纽约</a>总部位于美国的制药巨头股价上涨约12.7%,创下2009年3月以来的最佳单周涨幅。</blockquote></p><p> Among worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.</p><p><blockquote>在本周表现最差的公司中,两家新IPO的生物技术公司Instil Bio(纳斯达克股票代码:TIL)和Exscientia(纳斯达克股票代码:EXAI)脱颖而出,尽管它们在华尔街获得了良好的评级,但分别下跌了19.3%和约13.5%。与此同时,处方药比价平台运营商GoodRx Holdings(纳斯达克股票代码:GDRX)股价下跌约15.6%。</blockquote></p><p> Last week’s best performer, <a href=\"https://laohu8.com/S/BHG\">Bright Health Group</a>, crashed ~13.1%, hurt by the sole Sell rating issued by <a href=\"https://laohu8.com/S/GS\">Goldman Sachs</a> even as the investment bank kicked off its coverage on managed care with largely positive views.</p><p><blockquote>上周表现最好的,<a href=\"https://laohu8.com/S/BHG\">光明健康集团</a>,暴跌约13.1%,受到唯一卖出评级的伤害<a href=\"https://laohu8.com/S/GS\">高盛</a>尽管这家投资银行以基本积极的观点开始了对管理式医疗的报道。</blockquote></p><p> Allogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic <a href=\"https://laohu8.com/S/00699\">CAR</a> T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.</p><p><blockquote>Allogene Therapeutics(纳斯达克股票代码:ALLO)在ASH介绍实验性同种异体药物1期数据后股价下跌约12.3%<a href=\"https://laohu8.com/S/00699\">车</a>T疗法未能让投资者兴奋,其中包括Cathie Wood的Ark Investment Management,该公司几天后出售了约160万股该生物技术公司的股票。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源:<a href=\"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade\">Seeking Alpha</a></p>\n<p>为提升您的阅读体验,我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ORCL":"甲骨文","BK4534":"瑞士信贷持仓","CERN":"美国塞纳","ARNA":"阿里那","BK4007":"制药","BK4550":"红杉资本持仓","PFE":"辉瑞","BK4568":"美国抗疫概念","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://seekingalpha.com/news/3781487-novavax-vir-among-healthcare-gainers-pfizer-posts-best-rally-in-a-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122414343","content_text":"The healthcare stocks in the S&P 500 outperformed all other sectors in the broader index with a ~2.5% gain thanks mainly to M&A prospects. Healthcare technology, along with names battling the resurgence of COVID-19, led the gainers while the overall index fell ~1.9%.\nAmong stocks with more than $2B market capitalization and 100K average daily volume over the past week, Arena Pharmaceuticals dominated with a ~83.8% rise after Pfizer agreed to acquire it in a ~$6.7B deal with 100% premium for the biotech. Cerner also joined the M&A-driven rally to gain ~20.7% over the week amid reports of a potential ~$30B bid from Oracle for the electronic-medical-records company.\nVaccine developer, Novavax jumped ~30.5% as investors welcomed the WHO clearance for the company’s COVID-19 shot. Further gains for the Maryland-based biotech are likely when an expert panel of the European regulators is set to review the marketing authorization for the vaccine next week.\nBiohaven Pharmaceutical posted a ~25.2% weekly rise after the company announced the approval for NURTEC ODT (rimegepant) in Israel, making it the first regulatory win for the migraine drug outside the U.S. Meanwhile, Vir Biotechnology (NASDAQ:VIR) surged ~23.7% to stand among best gainers for the second week this month. More data emerged this week confirming the Omicron-neutralizing effect of the company’s COVID-19 therapy developed in partnership with GlaxoSmithKline (NYSE:GSK). Rounding out the top five gainers, Roivant Sciences added ~22.6%.\nNotable gainer: Pfizer (PFE) made headlines throughout the week, raising its sales guidance for the COVID-19 vaccine once again as the rapidly spreading Omicron variant highlighted the need for booster shots. Despite an abrupt end to its six-day rally on Friday, the New York-based pharma giant with a ~12.7% rise recorded its best weekly gain since March 2009.\nAmong worst performers of the week, two newly IPO’ed biotechs, Instil Bio (NASDAQ:TIL) and Exscientia (NASDAQ:EXAI), stood out, falling 19.3% and ~13.5%, respectively, despite their favorable ratings on Wall Street. Meanwhile, GoodRx Holdings (NASDAQ:GDRX), an operator of a price comparison platform for prescription medicine slumped ~15.6%.\nLast week’s best performer, Bright Health Group, crashed ~13.1%, hurt by the sole Sell rating issued by Goldman Sachs even as the investment bank kicked off its coverage on managed care with largely positive views.\nAllogene Therapeutics (NASDAQ:ALLO) dropped ~12.3% after the company’s ASH presentations on Phase 1 data for experimental allogeneic CAR T therapies failed to excite investors, including Cathie Wood’s Ark Investment Management, which sold ~1.6M shares of the biotech several days later.","news_type":1,"symbols_score_info":{"ARNA":0.9,"PFE":0.9,"ORCL":0.9,"CERN":0.9}},"isVote":1,"tweetType":1,"viewCount":2794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":693096362,"gmtCreate":1639921908676,"gmtModify":1639921908786,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Ftwwwwww","listText":"Ftwwwwww","text":"Ftwwwwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/693096362","repostId":"2192035909","repostType":4,"isVote":1,"tweetType":1,"viewCount":2855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602732859,"gmtCreate":1639064714525,"gmtModify":1639065935620,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602732859","repostId":"1181928624","repostType":4,"repost":{"id":"1181928624","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1639063477,"share":"https://www.laohu8.com/m/news/1181928624?lang=zh_CN&edition=full","pubTime":"2021-12-09 23:24","market":"us","language":"en","title":"Analysts Remain Bullish On Apple Over iPhone 13, AR Glasses, App Store<blockquote>分析师仍看好苹果iPhone 13、AR眼镜、App Store</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1181928624","media":"Benzinga","summary":"Analysts remained bullish on Apple Inc over iPhone 13 and court order in support of App Store.\n\nWedb","content":"<p>Analysts remained bullish on <b>Apple Inc</b> over iPhone 13 and court order in support of App Store.</p><p><blockquote>分析师仍看好<b>苹果公司</b>超过iPhone 13和法院命令支持App Store。</blockquote></p><p> <ul> <li><b>Wedbush</b> analyst Daniel Ives says that his Apple store checks, supply chain data, and iPhone order delays confirm his bullish view that demand is currently outstripping supply for iPhones 13 by roughly 10 million units globally.</li> <li>His iPhone 13 checks continue to be much stronger than expected, with his belief that Apple is now on pace to sell north of 40 million iPhones during the holiday season despite the chip shortage headwinds.</li> <li>The analyst estimates that there are roughly 15 million iPhone 13 upgrades in China alone for the December quarter as this critical region remains a significant source of strength for Apple.</li> <li>Based on his recent Asia checks, Ives also believes new product introductions like the highly anticipated AR headset Apple Glasses will make their debut in the second half of 2022. It could add $20 per share to the SOTP valuation of Apple, given this massive market opportunity and tapping the broader metaverse ecosystem.</li> <li>He has an Outperform rating and a price target of $200 on the shares, implying a 14.2% upside.</li> <li>The ninth Circuit Court of Appeals granted Apple a stay less than 24 hours before a court-ordered injunction was set to force the company to open its App Store up to alternative payment platforms via in-app links.</li> <li><b>Morgan Stanley</b> analyst Katy Huberty called the news \"an upside surprise\" that effectively allows Apple to maintain the status quo and reduces the impact of broader changes to App Store payment mechanisms until the Epic case appeal is resolved.</li> <li>Huberty, who thinks the resolution of the Epic case appeal is \"likely months to years away,\" keeps an Overweight rating and $200 price target on Apple shares.</li> <li>Huberty pointed out that she has already included a $1.5 billion headwind to App Store revenue in her Services forecast.</li> </ul></p><p><blockquote><ul><li><b>韦德布什</b>分析师Daniel Ives表示,他的苹果商店检查、供应链数据和iPhone订单延迟证实了他的看涨观点,即目前全球iPhone 13的需求超过供应约1000万部。</li><li>他的iPhone 13支票继续远强于预期,他相信尽管面临芯片短缺的不利因素,苹果目前仍有望在假期期间售出超过4000万部iPhone。</li><li>该分析师估计,仅在中国,12月份季度就有大约1500万部iPhone 13升级,因为这个关键地区仍然是苹果的重要实力来源。</li><li>根据他最近在亚洲的考察,Ives还认为,备受期待的AR耳机苹果眼镜等新产品将于2022年下半年首次亮相。鉴于这一巨大的市场机会并利用更广泛的元宇宙生态系统,它可能会使苹果的SOTP估值每股增加20美元。</li><li>他对该股给予跑赢大盘评级,目标价为200美元,这意味着上涨14.2%。</li><li>在法院下令强制该公司通过应用内链接向替代支付平台开放其应用商店之前不到24小时,第九巡回上诉法院准予苹果暂缓执行。</li><li><b>摩根士丹利</b>分析师Katy Huberty称这一消息是“一个上行惊喜”,它有效地让苹果维持现状,并减少了应用商店支付机制更广泛变化的影响,直到Epic案件上诉得到解决。</li><li>休伯蒂认为史诗案件上诉的解决“可能需要几个月到几年的时间”,他维持苹果股票的跑赢大盘评级和200美元的目标价。</li><li>Huberty指出,她已经在服务预测中纳入了App Store收入15亿美元的阻力。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Analysts Remain Bullish On Apple Over iPhone 13, AR Glasses, App Store<blockquote>分析师仍看好苹果iPhone 13、AR眼镜、App Store</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnalysts Remain Bullish On Apple Over iPhone 13, AR Glasses, App Store<blockquote>分析师仍看好苹果iPhone 13、AR眼镜、App Store</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2021-12-09 23:24</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p>Analysts remained bullish on <b>Apple Inc</b> over iPhone 13 and court order in support of App Store.</p><p><blockquote>分析师仍看好<b>苹果公司</b>超过iPhone 13和法院命令支持App Store。</blockquote></p><p> <ul> <li><b>Wedbush</b> analyst Daniel Ives says that his Apple store checks, supply chain data, and iPhone order delays confirm his bullish view that demand is currently outstripping supply for iPhones 13 by roughly 10 million units globally.</li> <li>His iPhone 13 checks continue to be much stronger than expected, with his belief that Apple is now on pace to sell north of 40 million iPhones during the holiday season despite the chip shortage headwinds.</li> <li>The analyst estimates that there are roughly 15 million iPhone 13 upgrades in China alone for the December quarter as this critical region remains a significant source of strength for Apple.</li> <li>Based on his recent Asia checks, Ives also believes new product introductions like the highly anticipated AR headset Apple Glasses will make their debut in the second half of 2022. It could add $20 per share to the SOTP valuation of Apple, given this massive market opportunity and tapping the broader metaverse ecosystem.</li> <li>He has an Outperform rating and a price target of $200 on the shares, implying a 14.2% upside.</li> <li>The ninth Circuit Court of Appeals granted Apple a stay less than 24 hours before a court-ordered injunction was set to force the company to open its App Store up to alternative payment platforms via in-app links.</li> <li><b>Morgan Stanley</b> analyst Katy Huberty called the news \"an upside surprise\" that effectively allows Apple to maintain the status quo and reduces the impact of broader changes to App Store payment mechanisms until the Epic case appeal is resolved.</li> <li>Huberty, who thinks the resolution of the Epic case appeal is \"likely months to years away,\" keeps an Overweight rating and $200 price target on Apple shares.</li> <li>Huberty pointed out that she has already included a $1.5 billion headwind to App Store revenue in her Services forecast.</li> </ul></p><p><blockquote><ul><li><b>韦德布什</b>分析师Daniel Ives表示,他的苹果商店检查、供应链数据和iPhone订单延迟证实了他的看涨观点,即目前全球iPhone 13的需求超过供应约1000万部。</li><li>他的iPhone 13支票继续远强于预期,他相信尽管面临芯片短缺的不利因素,苹果目前仍有望在假期期间售出超过4000万部iPhone。</li><li>该分析师估计,仅在中国,12月份季度就有大约1500万部iPhone 13升级,因为这个关键地区仍然是苹果的重要实力来源。</li><li>根据他最近在亚洲的考察,Ives还认为,备受期待的AR耳机苹果眼镜等新产品将于2022年下半年首次亮相。鉴于这一巨大的市场机会并利用更广泛的元宇宙生态系统,它可能会使苹果的SOTP估值每股增加20美元。</li><li>他对该股给予跑赢大盘评级,目标价为200美元,这意味着上涨14.2%。</li><li>在法院下令强制该公司通过应用内链接向替代支付平台开放其应用商店之前不到24小时,第九巡回上诉法院准予苹果暂缓执行。</li><li><b>摩根士丹利</b>分析师Katy Huberty称这一消息是“一个上行惊喜”,它有效地让苹果维持现状,并减少了应用商店支付机制更广泛变化的影响,直到Epic案件上诉得到解决。</li><li>休伯蒂认为史诗案件上诉的解决“可能需要几个月到几年的时间”,他维持苹果股票的跑赢大盘评级和200美元的目标价。</li><li>Huberty指出,她已经在服务预测中纳入了App Store收入15亿美元的阻力。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1181928624","content_text":"Analysts remained bullish on Apple Inc over iPhone 13 and court order in support of App Store.\n\nWedbush analyst Daniel Ives says that his Apple store checks, supply chain data, and iPhone order delays confirm his bullish view that demand is currently outstripping supply for iPhones 13 by roughly 10 million units globally.\nHis iPhone 13 checks continue to be much stronger than expected, with his belief that Apple is now on pace to sell north of 40 million iPhones during the holiday season despite the chip shortage headwinds.\nThe analyst estimates that there are roughly 15 million iPhone 13 upgrades in China alone for the December quarter as this critical region remains a significant source of strength for Apple.\nBased on his recent Asia checks, Ives also believes new product introductions like the highly anticipated AR headset Apple Glasses will make their debut in the second half of 2022. It could add $20 per share to the SOTP valuation of Apple, given this massive market opportunity and tapping the broader metaverse ecosystem.\nHe has an Outperform rating and a price target of $200 on the shares, implying a 14.2% upside.\nThe ninth Circuit Court of Appeals granted Apple a stay less than 24 hours before a court-ordered injunction was set to force the company to open its App Store up to alternative payment platforms via in-app links.\nMorgan Stanley analyst Katy Huberty called the news \"an upside surprise\" that effectively allows Apple to maintain the status quo and reduces the impact of broader changes to App Store payment mechanisms until the Epic case appeal is resolved.\nHuberty, who thinks the resolution of the Epic case appeal is \"likely months to years away,\" keeps an Overweight rating and $200 price target on Apple shares.\nHuberty pointed out that she has already included a $1.5 billion headwind to App Store revenue in her Services forecast.","news_type":1,"symbols_score_info":{"AAPL":0.9}},"isVote":1,"tweetType":1,"viewCount":3449,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608746416,"gmtCreate":1638795767490,"gmtModify":1638795979841,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Rise backkkkkkkk","listText":"Rise backkkkkkkk","text":"Rise backkkkkkkk","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/608746416","repostId":"2189955504","repostType":4,"isVote":1,"tweetType":1,"viewCount":2778,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601020506,"gmtCreate":1638460564929,"gmtModify":1638460583872,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Good move","listText":"Good move","text":"Good move","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601020506","repostId":"1144502876","repostType":4,"isVote":1,"tweetType":1,"viewCount":2946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875477032,"gmtCreate":1637682230794,"gmtModify":1637682230794,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Rocketttt","listText":"Rocketttt","text":"Rocketttt","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875477032","repostId":"1129561166","repostType":4,"isVote":1,"tweetType":1,"viewCount":3261,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875474119,"gmtCreate":1637682207932,"gmtModify":1637682207932,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875474119","repostId":"1127011683","repostType":4,"isVote":1,"tweetType":1,"viewCount":3295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875474975,"gmtCreate":1637682191261,"gmtModify":1637682191261,"author":{"id":"3574938595128690","authorId":"3574938595128690","name":"niclam","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574938595128690","idStr":"3574938595128690"},"themes":[],"title":"","htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/875474975","repostId":"1192119389","repostType":4,"repost":{"id":"1192119389","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637679057,"share":"https://www.laohu8.com/m/news/1192119389?lang=zh_CN&edition=full","pubTime":"2021-11-23 22:50","market":"us","language":"en","title":"Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192119389","media":"Tiger Newspress","summary":"Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.\n\nMiz","content":"<p>Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<img src=\"https://static.tigerbbs.com/a002ee881fc7645aa99d269b0c161b2a\" tg-width=\"867\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote></p><p> <ul> <li><b>Mizuho</b> analyst Vijay Rakesh upgraded <b>Western Digital Corp</b> to Buy from Neutral with a price target of $75, up from $55, implying a 31.7% upside.</li> </ul> <ul> <li><b>Mizuho</b> analyst Vijay Rakesh upgraded <b>Micron Technology Inc</b> to Buy from Neutral with a price target of $95, up from $75, implying a 13.3% upside.</li> </ul></p><p><blockquote><ul><li><b>瑞穗</b>分析师Vijay Rakesh升级<b>西部数据公司</b>从中性买入,目标价从55美元上调至75美元,意味着上涨31.7%。</li></ul><ul><li><b>瑞穗</b>分析师Vijay Rakesh升级<b>美光科技公司</b>从中性买入,目标价从75美元上调至95美元,意味着上涨13.3%。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWestern Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-23 22:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.<img src=\"https://static.tigerbbs.com/a002ee881fc7645aa99d269b0c161b2a\" tg-width=\"867\" tg-height=\"617\" referrerpolicy=\"no-referrer\"></p><p><blockquote>西部数据股价早盘涨超7%,美光科技涨近4%。</blockquote></p><p> <ul> <li><b>Mizuho</b> analyst Vijay Rakesh upgraded <b>Western Digital Corp</b> to Buy from Neutral with a price target of $75, up from $55, implying a 31.7% upside.</li> </ul> <ul> <li><b>Mizuho</b> analyst Vijay Rakesh upgraded <b>Micron Technology Inc</b> to Buy from Neutral with a price target of $95, up from $75, implying a 13.3% upside.</li> </ul></p><p><blockquote><ul><li><b>瑞穗</b>分析师Vijay Rakesh升级<b>西部数据公司</b>从中性买入,目标价从55美元上调至75美元,意味着上涨31.7%。</li></ul><ul><li><b>瑞穗</b>分析师Vijay Rakesh升级<b>美光科技公司</b>从中性买入,目标价从75美元上调至95美元,意味着上涨13.3%。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MU":"美光科技","WDC":"西部数据"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192119389","content_text":"Western Digital shares rose more than 7% in early trading and Micron Technology rose nearly 4%.\n\nMizuho analyst Vijay Rakesh upgraded Western Digital Corp to Buy from Neutral with a price target of $75, up from $55, implying a 31.7% upside.\n\n\nMizuho analyst Vijay Rakesh upgraded Micron Technology Inc to Buy from Neutral with a price target of $95, up from $75, implying a 13.3% upside.","news_type":1,"symbols_score_info":{"MU":0.9,"WDC":0.9}},"isVote":1,"tweetType":1,"viewCount":2984,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"following","isTTM":false}